Knight Reports Third Quarter Financial 2015 Results
(firmenpresse) - MONTREAL, CANADA -- (Marketwired) -- 11/11/15 -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or the "Company"), a leading Canadian specialty pharmaceutical company, today reported its third quarter ended September 30, 2015 financial results.
Third Quarter 2015 Highlights
Product Development
Corporate Development
Other Developments
Subsequent to the Quarter Ended September 30, 2015 Highlights
Third Quarter 2015 Financial Results Reported in Canadian Dollars
The Company''s financial statements for the period ended September 30, 2015 have been prepared in accordance with IAS 34, Interim Financial Reporting.
For the quarter ended September 30, 2015, the Company reported revenues of $114 thousand and net income of $6.3 million. As at September 30, 2015, the Company had $445.9 million in cash and marketable securities and 103,450,125 common shares outstanding.
"This quarter was marked by our strategic and financial partnership with Medison, often referred to as the Paladin of Israel," said Jonathan Ross Goodman, President and CEO of Knight. "Looking ahead, our team will remain disciplined, yet aggressive in our pursuit of opportunities to expand our promising pipeline of innovative pharmaceuticals."
Conference Call Notice
Knight will host a conference call to discuss its third quarter results today at 8:30 am ET. Investors and other interested parties may call 877-223-4471 (Operator Assisted Toll-Free) or 647-788-4922 (local or international).
A taped replay of the conference call will be available from today at 11:30 a.m. ET until Wednesday, December 9, 2015 at 11:59 p.m. ET. To access the replay, please call 1-800-585-8367 or 416-621-4642 and use access code 9981901.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight''s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the Company''s web site at or .
Forward-Looking Statement
This document contains forward-looking statements for the Company and its subsidiaries. These forward looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these assumptions regarding future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in the Company''s Annual Report and in the Company''s Annual Information Form for the year ended December 31, 2014. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
Knight Therapeutics Inc.
INTERIM CONSOLIDATED BALANCE SHEETS
As at
(In thousands of Canadian dollars)
(Unaudited)
Knight Therapeutics Inc.
INTERIM CONSOLIDATED STATEMENTS OF INCOME
(In thousands of Canadian dollars, except for share and per share amounts)
(Unaudited)
Knight Therapeutics Inc.
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands of Canadian dollars)
(Unaudited)
Knight Therapeutics Inc.
INTERIM CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS'' EQUITY
(In thousands of Canadian dollars)
(Unaudited)
Knight Therapeutics Inc.
INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS
(In thousands of Canadian dollars)
(Unaudited)
Contacts:
Knight Therapeutics Inc.
Jeffrey Kadanoff, P.Eng., MBA
Chief Financial Officer
514-484-GUD1 (4831)
514-481-4116 (FAX)
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 11.11.2015 - 05:00 Uhr
Sprache: Deutsch
News-ID 1398577
Anzahl Zeichen: 2242
contact information:
Contact person:
Town:
MONTREAL, CANADA
Phone:
Kategorie:
Drugs
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Knight Reports Third Quarter Financial 2015 Results
"
steht unter der journalistisch-redaktionellen Verantwortung von
Knight Therapeutics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
